BR9507010A - Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF - Google Patents

Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF

Info

Publication number
BR9507010A
BR9507010A BR9507010A BR9507010A BR9507010A BR 9507010 A BR9507010 A BR 9507010A BR 9507010 A BR9507010 A BR 9507010A BR 9507010 A BR9507010 A BR 9507010A BR 9507010 A BR9507010 A BR 9507010A
Authority
BR
Brazil
Prior art keywords
hbf
globin
ameliorating
processes
individual
Prior art date
Application number
BR9507010A
Other languages
English (en)
Inventor
Ada Rephaeli
Abraham Nudelman
Mattyahu Shaklai
Original Assignee
Ada Rephaeli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ada Rephaeli filed Critical Ada Rephaeli
Publication of BR9507010A publication Critical patent/BR9507010A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9507010A 1994-03-07 1995-03-06 Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF BR9507010A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/206,690 US5569675A (en) 1994-03-07 1994-03-07 Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
PCT/US1995/002769 WO1995024189A1 (en) 1994-03-07 1995-03-06 Increasing fetal hemoglobin levels using carboxylic esters

Publications (1)

Publication Number Publication Date
BR9507010A true BR9507010A (pt) 1997-09-16

Family

ID=22767519

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507010A BR9507010A (pt) 1994-03-07 1995-03-06 Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF

Country Status (11)

Country Link
US (1) US5569675A (pt)
EP (1) EP0793488A1 (pt)
JP (1) JPH09510202A (pt)
KR (1) KR970701540A (pt)
CN (1) CN1148338A (pt)
AU (1) AU1980695A (pt)
BR (1) BR9507010A (pt)
CA (1) CA2184695A1 (pt)
IL (1) IL112896A0 (pt)
MX (1) MX9603885A (pt)
WO (1) WO1995024189A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880152A (en) * 1995-10-06 1999-03-09 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5883123A (en) * 1995-10-06 1999-03-16 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5912269A (en) * 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5827544A (en) * 1995-10-10 1998-10-27 The Arab Pharmaceutical Manufacturing Co. Ltd. Different way of management of neonatal hyperbilirubinemia
US5763488A (en) * 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
CN1109545C (zh) * 1996-12-13 2003-05-28 科学与工业研究会 螯合铁的制剂及其制备方法
US6130248A (en) * 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6225350B1 (en) 1998-03-10 2001-05-01 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
NZ513329A (en) * 1999-02-05 2003-11-28 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US6693132B2 (en) * 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
ITTO20020684A1 (it) * 2002-07-31 2004-02-01 Associazione Veneta Per La Lotta Alla Talassemia Nuovo uso dell'angelicina e di suoi analoghi strutturali.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1658074B1 (en) * 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US20070185045A1 (en) * 2006-02-06 2007-08-09 Ratcliffe Peter J Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2007133653A2 (en) * 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
US9095565B2 (en) * 2006-05-09 2015-08-04 Phoenicia Biosciences, Inc. Methods for treating blood disorders
US20080008651A1 (en) * 2006-05-25 2008-01-10 The Regents Of The University Of Michigan Screening Methods and Transgenic Animals for the Treatment of Beta-Globin Related Disease and Conditions
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin
BR112012000254A2 (pt) 2009-07-08 2016-02-16 Dermira Canada Inc análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
US9713602B1 (en) * 2016-03-15 2017-07-25 National Sun Yat-Sen University Method for facilitating the oxygen release of hemoglobin-based blood substitutes
US11179379B2 (en) 2017-01-30 2021-11-23 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
ES2045028T3 (es) * 1987-07-30 1994-01-16 Univ Bar Ilan Esteres de acidos carboxilicos biologicamente activos.
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5439939A (en) * 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
JPH09509139A (ja) * 1993-11-10 1997-09-16 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 酪酸エステル細胞分化薬

Also Published As

Publication number Publication date
US5569675A (en) 1996-10-29
KR970701540A (ko) 1997-04-12
JPH09510202A (ja) 1997-10-14
CA2184695A1 (en) 1995-09-14
MX9603885A (es) 1997-05-31
WO1995024189A1 (en) 1995-09-14
IL112896A0 (en) 1995-06-29
EP0793488A1 (en) 1997-09-10
AU1980695A (en) 1995-09-25
EP0793488A4 (pt) 1997-09-10
CN1148338A (zh) 1997-04-23

Similar Documents

Publication Publication Date Title
BR9507010A (pt) Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
BR9702541A (pt) Composição cosmética e/ou dermatológica utilização da composição e processo para tratamento não-terapêutico cosmético
DE69726245D1 (de) Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf
GB2114580B (en) Composition intended for treating the hair skin or nails containing at least one cationic polymer and at least one anionic latex
DE69435276D1 (de) Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie
BR9306067A (pt) Processos para proporcionar efeito analgésico e para o tratamento ou prevenção de pirexia em seres humanos e composiç o anagésica e antipirética para o tratamento de seres humanos
BR9604959A (pt) Composição e método para o tratamento de desensibilização de dentes
TR28603A (tr) Polimerlerin karistirilmasi, aprelenmesi ve ucuculuklarinin alinmasi icin uygun aygit.
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
BR9508584A (pt) Processo para tratamento de um indivíduo para endotoxemia e para alivio utilizável no tratamento de endotoxemia
DE69513637T2 (de) Zubereitung und Vorrichtung zur Entfernung von überschüssigen Wasserstoffionen in Menschen
BR8901135A (pt) Composicao para condicionamento de tecido e processo para tratar tecidos
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
DE69624214D1 (de) Hormonale medikamente und deren verwendung zur behebung von östrogenmangelerscheinungen
AT378462B (de) Vorrichtung zur gleichmaessigen dosierung, verteilung und aufbringung von fluessig formulierten schutzstoffen, insbesondere beizmitteln
PL324929A1 (en) Cosmetic method of treating and preventing the symptoms of skin ageing
BR9501191A (pt) Processo para o tratamento de minério fino e instalação para condução do processo
DE9311721U1 (de) Vorrichtung für eine Oberflächenbehandlung freistehender im wesentlichen senkrechter Wände, insbesondere von Schiffen
EE9700037A (et) Jäätmete töötlemise meetod ning meetodis kasutatav seadmestik
DE69733623D1 (de) Snoopbus für zerteite transaktionen und arbitrierungsverfahren
BA98363A (bs) Postupak i uredaj za tretiranje koze i tome slicno
EP0893123A4 (en) MEANS OF PREVENTIVE AND CURATIVE TREATMENT OF CONDITIONS RELATED TO DIFFERENT FORMS OF AGING OF THE ORGANISM
NO996496D0 (no) (S) 2-metylamino-2-fenyl-n-butyl 3,4,5-trimetoksybenzoat samt anvendelse av denne ved behandling av kronisk smerte
BR8604206A (pt) Composicoes microbicidas e processo para tratamento microbicida em sistemas aquosos

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law